Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00435487
Status:
TERMINATED
Last Update Posted:
2011-10-17
First Post:
2007-02-13
Brief Title:
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Prospective Randomized Phase IV Open Label Comparative Study Of Dalteparin vs Unfractionated Heparin In High Risk Patients Of Non-ST Elevation Acute Coronary Syndromes Intended For Early Invasive Strategy
Status:
TERMINATED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
See termination reason in detailed description
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions angioplasty or bypass surgery
Detailed Description:
The study was prematurely discontinued on November 30 2008 due to delay in meeting pre-defined protocol recruitment milestones There were no safety concerns regarding the study in the decision to terminate the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None